You are on page 1of 8

Date

Ordred
Drug name Action Indication Nursing Responsibilities
July 4,5,6 Furosemide
40mgI! "6
Classifcatio
n:
#ardio$ascul
ar drug %
&oop
Diuretics
In'ibits sodium and c'loride
reabsorption at pro(imal tubules,
distal tubules and ascending
loop o) *enley leading to
e(cretion o) +ater toget'er +it'
sodium, c'loride and potassium,
diuretics, anti'ypertensi$e,
Absorption: -I tract .60/%00/1
I2I! .administration1
Distribution: 35/ protein
bound
Metabolism: &i$er .40/%40/1
Excretion: 50/%50/ 6idneys
Half-life: 40 min to 7 'our
8O I2 I!
Onset 7'r 40
mi
ns
5
min
8ea6 7%
9'r
:n
6no
+n
40
min
s
Duratio
n
6%
5'r
4%5
'rs
9
'rs
;reatment o) edema
associated +it'
congesti$e 'eart
)ailure, 'ypertension,
Instruct patient to ta6e +it'
)ood or mil6 i) -I symptoms
o) nausea and anore(ia,
In)orm patient t'at t'is drug
causes a loss o) potassium,
t'ere)ore )ood ric' in
potassium s'ould added to
t'e diet,
;eac' patient not to use
alco'ol or any O;#
medication +it'out
p'ysician<s appro$al because
o) t'e danger o) serious drug
reaction,
Date Ordred Drug name Action Indication Nursing Responsibilities
July 4,5,6 Aldactone
95mgtab 7
tab =ID
Classifcatio
n:
#ardio$ascul
ar drugs >
Aldosterone
Antagonist
Antagoni?e aldosterone in
t'e distal tubules, increasing
sodium and +ater e(cretion,
Absorption: -I tract@ +ell
absorbed
Distribution: crosses
placenta
Metabolism: li$er to
canrenone
Excretion: Renal@ breast
mil6
*al)%&i)eA 79%94 'rs
.canrenone1
Onset 94%45 'rs
8ea6 45%09 'rs
Duration :n6no+n
2anagement o)
edematous
condition in #*F,
treatment o)
'ypo6alemia,
Instruct patient to ta6e
medication early in day to pre$ent
need to urinate at nig't, I) second
close is needed, tell 'im to ta6e
)ood in early a)ternoon,
Barn patient t'at a$oid t'at a$oid
dri$ing or ot'er 'a?ardous
acti$ities i) alertness re"uire,
di??iness and con)usion may
occur,
Ad$ice patient not to use alco'ol,
or O;# medication +it'out
p'ysician<s order@ serious drug
reaction may occur,

Date
Ordred
Drug name Action Indication Nursing Responsibilities
July
4,5,6
Cnalapril
70mgtab D
tab OD
Classifcatio
n:
#ardio$ascul
ar drug > A#C
In'ibitors
In'ibit angiotensin con$erting en?yme
,pre$enting t'e con$ersion o) angiotensin 7 to
angiotensin 9, a potent $asoconstrictor,
Reduced )ormation o) angiotensin 9 decrease
perip'eral resistance, t'us decreasing
aldosterone secretion, Eelecti$ely suppresses
renin%angiotensin%aldosterone,
Absorption: Bell, 60/ .8O1, #omplete .I!1
Distribution: :n6no+n
Metabolism: &i$er .to acti$e metabolite%
enalaprilat1
Excretion: Fidney .60/%enalaprilat, 90/%
enalapril1
Half-life: Cnalaprilat 79 'rs increase in renal
disease,
8O I!
Onset 7'r 75
min
8ea6 4%6
'rs
7%4
'rs
Duration 94
'rs
6 'rs
;reatment o)
'ypertension
and 'eart
)ailure,
Ad$ice patient to monitor
to c'ange position slo+ly
to minimi?e ort'ostatic
'ypotension,
Ad$ice patient to a$oid
'a?ardous acti$ities
because drug may cause
di??iness, )ainting, lig't
'eadness especially
during 7
st
)e+ days o)
t'erapy,
;eac' patient not to use
O;# drugs products un
less directed by p'ysician
A$oid potassium, salt
substitute@ serious side
eGects can occur
Date
Ordred
Drug name Action, 8'armaco6inetics, 8'armacodynamics Indication Nsg Responsibilities
July 4,5,6 &ano(in
0,95mgtab
7 tab OD
Classifcat
ion:
#ardio$asc
ular drug >
#ardiac
-lycoside
In'ibits sodium%potassium acti$ated adenosine
trip'osp'ate, t'reby allo+ing inHu( o) calcium
into t'e intracellular space .cytoplasm1, more
a$ailable calcium promotes increased )orce o)
myocardial contraction resulting to increased
cardiac output, It also acts on t'e #NE to
en'ance $agal tone, causing t'e decrease o)
conduction speed bet+een t'e EA and A! nodes,
;'is $agal stimulation decreaset'e cardiac rate
.negati$e c'ronotropic eGectto pre$ent
arr'yt'mia,
Absorption: 60/%55/ .tablet1, 30/%700/
.capsule1
DistributionA Bide, 90/%95/ protein bound
Metabolism: &i$er and intestinal bacteria .small
amount1
Excretion: Fidneys
Half-life: 40%40 'rs
8O I!
Onset 40min%
7'r and
40 min
5%40 min
8ea6 9%6 'rs 7%4 'rs
#'ronic
cardiac )ailure
+it' atrial
Ibrillation,
$entricular
dilation,
supra$entricul
ar
arr'yt'mias
-et t'e cardiac
rate be)ore
drin6 t'e
medication,
;eac' patient
to ta6e
medication at
t'e same time
eac' day,
;a6e missed
dose +it'in 79
'rs and do not
double dose,
duratio
n
4%4 days 4%4 'rs
Date
Ordred
Drug
name
Action Indication Nsg Responsibities
July 4,5,6 #oumadin
5mg 7 tab
2on and
Fri 79 tab
;ues,Bed,
;'urs,Eat,
Eun 74
tab
#lassiIcati
on
Anti
#oagulant
In'ibits $itamin F dependent acti$ation o)
clotting )actors II,!III,IJ,J )ormed in t'e li$er, It
reduces t'e ability o) blood to clot,
Absorption: Rapid and complete
Distribution: 33/ plasma protein binding
Metabolism: &i$er
Excretion: &i$er and 6idney .acti$e,
inacti$e,metabolites1
Half-life: 7%4 days
8O I!
Onset 79%4
days
un6no+n
8ea6 79 %4
days
un6no+n
8rop'yla(is
andor
treatment o)
$enous
t'rombosis,
pulmonary
embolism, atrial
Ibrillation +it'
emboli?atio,
adKunct in
prop'yla(is o)
systemic
embolism a)ter
myocardial
in)arction
;ell patient to
a$oid O;#
preparation
t'at may
contain aspirin
or salicylate
+'ic' may
interact +it'
+ar)arin,
Ad$ise patient
to use so)t
bristle
toot'brus' and
a$oid ra?or or
s'arp obKect to
minimi?e t'e
ris6 o)
bleeding,
Duration 9%5 days un6no+n

You might also like